Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Breastfeeding During Endocrine Therapy Interruption Is Feasible, Does Not Adversely Affect Recurrence Rates in HR+ Breast Cancer

September 24th 2024

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

Dato-DXd Fails to Show OS Benefit in Pretreated HR+/HER2-Low or -Negative Metastatic Breast Cancer

September 23rd 2024

No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer.

Dr Lim on the Significance of the FDA Approval of Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 23rd 2024

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

The OncFive: Top Oncology Articles for the Week of 9/15

September 21st 2024

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

Pelareorep Plus Chemo Improves OS in Endocrine-Refractory HR+/HER2– Advanced Breast Cancer

September 19th 2024

Pelareorep plus paclitaxel improved overall survival in endocrine-refractory, hormone receptor–positive/HER2-negative advanced breast cancer.

Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer

September 18th 2024

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

September 18th 2024

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

September 18th 2024

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 17th 2024

The FDA approved adjuvant ribociclib plus an aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

Dr Yuan on the Evolution of Radiation Therapy Approaches in Breast Cancer

September 17th 2024

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Abemaciclib/ET Combo Improves Responses vs Chemo in Aggressive HR+/HER2– Breast Cancer

September 16th 2024

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

Adjuvant Ribociclib Sustains DFS, DDFS Benefit in HR+/HER2– Breast Cancer

September 16th 2024

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.

Dr Tarantino on Advances Allowing for Tailored Treatment in HER2+ Breast Cancer

September 16th 2024

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Dr Yuan on the Investigation of Adjuvant CDK4/6 Inhibition in Breast Cancer

September 16th 2024

Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.

T-DXd Delays Time to Deterioration in Functioning, Pain in HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

September 15th 2024

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC

September 15th 2024

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

Neoadjuvant Dato-DXd Plus Durvalumab Shows Variable pCR Rates in Stage II/III Breast Cancer

September 14th 2024

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

Nuances of HER2 Expression Underscore Need for More Precise Testing in Breast Cancer

September 11th 2024

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

September 11th 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Bria-IMT Plus Checkpoint Inhibition Maintains Favorable OS in Metastatic Breast Cancer

September 11th 2024

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.